Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

Genenta Science S.p.A. (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the Securities and Exchange Commission ("SEC") on May 2, 2022. The annual report can be accessed on the Company`s investor relations website at https://ir.genenta.com/financial-information/sec-filings as well as the SEC`s website at http://www.sec.gov.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company`s IR Department at mailto:ir@xiaoying.com.https://ir.genenta.com/ir-resources/investor-contact.